Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy

(2022) Zi-Jie Long et al.   MOLECULAR THERAPY

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

(2021) Thomas W. Flaig et al.   CLINICAL CANCER RESEARCH

A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.

(2021) Daniel M. Geynisman et al.   JOURNAL OF CLINICAL ONCOLOGY

Paradigms on Immunotherapy Combinations with Chemotherapy

(2021) Diego Salas-Benito et al.   Cancer Discovery

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

(2021) Jie Wang et al.   JAMA Oncology

Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?

(2021) Filippo Pederzoli et al.   EUROPEAN UROLOGY

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

(2021) Arjun Vasant Balar et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

(2021) Xavier Garcia del Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer

(2021) Tracy L. Rose et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.

(2021) Matt D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

(2021) Thomas Powles et al.   LANCET ONCOLOGY

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors

(2021) Filippo Pietrantonio et al.   Journal for ImmunoTherapy of Cancer

5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer

(2021) Jiao Hu et al.   BMC Medicine

Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer has no value for treatment decisions and low correlation with nodal status

(2021) S. Tenninge et al.   Scandinavian Journal of Urology

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study

(2021) Wenqun Xing et al.   Frontiers in Immunology

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

(2021) G. Mountzios et al.   ESMO Open

Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).

(2020) Richard Cathomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.

(2020) Shilpa Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

Tislelizumab: First Approval

(2020) Arnold Lee et al.   DRUGS

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

(2020) Matthew D Galsky et al.   LANCET

Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response

(2020) Sandrine Ragu et al.   Genes

Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy

(2020) Sang Hyung Lee et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

(2020) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer

(2020) Marco Bandini et al.   JNCI-Journal of the National Cancer Institute

Computerized tomography before the final treatment cycle of neoadjuvant chemotherapy or induction chemotherapy in muscle- invasive urinary bladder cancer, cannot predict pathoanatomical outcomes and does not reflect prognosis—results of a single centre retrospective prognostic study

(2020) Haben Mogos et al.   Translational Andrology and Urology

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

(2020) Dingwei Ye et al.   CANCER SCIENCE

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

(2020) Christian Pfister et al.   EUROPEAN UROLOGY

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

(2019) Alberto Martini et al.   CANCER

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study

(2019) Andrea Necchi et al.   EUROPEAN UROLOGY

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

(2018) Yi-Mi Wu et al.   CELL

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

76PTislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study

(2018) S Sandhu et al.   ANNALS OF ONCOLOGY

LBA33A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)

(2018) C J Hoimes et al.   ANNALS OF ONCOLOGY

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

(2018) Andrea Necchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World

(2017) Sham Mailankody et al.   JAMA Oncology

Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder

(2015) S Hafeez et al.   BRITISH JOURNAL OF CANCER

Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Is Low Among Major European Centres: Results of a Feasibility Questionnaire

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

(2010) Ganesh V. Raj et al.   CANCER

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH